Mizuho initiates Nurix stock coverage with Outperform rating on BTK inhibitor potential
PositiveFinancial Markets

Mizuho has begun coverage of Nurix Therapeutics, giving it an 'Outperform' rating due to the promising potential of its BTK inhibitor. This is significant as it highlights investor confidence in Nurix's innovative approach to treating diseases, which could lead to advancements in patient care and potentially lucrative returns for investors.
— Curated by the World Pulse Now AI Editorial System